Clinical Trials Directory

Trials / Completed

CompletedNCT05602428

Analysis of Clinical Effect of Subanesthetic Dose of Esketamine Combined With Hip Capsule Peripheral Nerve Block in Elderly Patients Undergoing Total Hip Arthroplasty

Traditional Chinese Medicine Hospital of Changzhou Affiliated to Nanjing University of Traditional Chinese Medicine

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
120 (actual)
Sponsor
Changzhou Traditional Chinese Medicine Hospital Affiliated to Nanjing University of Chinese Medicine · Academic / Other
Sex
All
Age
60 Years
Healthy volunteers
Not accepted

Summary

To observe the clinical effect of esketamine combined with hip capsule peripheral nerve block in elderly patients undergoing total hip arthroplasty. A total of 120 elderly patients who underwent total hip arthroplasty in our hospital from January 2020 to May 2021 were randomly divided into three groups, 40 cases in each group. The observation group A was treated with esketamine subanesthetic dose combined with hip capsule peripheral nerve block, the control group B was treated with esketamine subanesthetic dose combined with lumbar plexus block, and the control group C was treated with esketamine subanesthetic dose for general anesthesia. The onset time of anesthesia, duration of block, postoperative recovery time, postoperative extubation time, MAP and HR indexes before anesthesia (T0), during skin incision (T1), 30 minutes after the start of surgery (T2), and at the end of surgery (T3) were recorded in the three groups, and the VAS score and Ramsay score at 0.5 h, 2 h, 6 h, 12 h, and 24 h after surgery, as well as the incidence of postoperative adverse reactions were recorded in the three groups.

Conditions

Interventions

TypeNameDescription
DRUGesketamine sub-anesthetic,the use of esketamine sub-anesthetic dose combined with hip capsule peripheral nerve block
DRUGesketamine sub-anestheticEsketamine subanesthetic dose combined with lumbar plexus block was used
DRUGesketamine sub-anestheticgeneral anesthesia was performed with esketamine subanesthetic dose.

Timeline

Start date
2020-01-01
Primary completion
2021-05-31
Completion
2021-05-31
First posted
2022-11-02
Last updated
2022-11-02

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05602428. Inclusion in this directory is not an endorsement.